Table 2.
Representative recent phase ≥ II clinical trials for recurrent glioblastoma patients evaluating non-angiogenic, biologic-based therapeutics
| Agent | Patients (n) | Response Criteria | ORR (%) | Durability of ORR | PFS-6 (%) | Citation |
|---|---|---|---|---|---|---|
| AMG102 | 61 | Macdonald | 0 | Not applicable | 15.0–17.9 | Wen, 201132 |
| Cilengitide | 81 | Macdonald | 9 | Median: 17 months | 10–15% | Reardon, 200833 |
| Cis-retinoic acid + celecoxib | 25 | Macdonald | 0 | Not applicable | 19 | Levin, 200634 |
| Enzastaurin | 174 | Levin | 2.9 | Not stated | 11 | Wick, 201016 |
| Erlotinib | 54 | Macdonald | 3.7 | Not stated | 11.4 | Van den Bent, 200935 |
| Erlotinib | 48 | WHO | 6.3 | Median: 7 months | 18.3 | Yung, 201036 |
| Erlotinib + sirol | 32 | Macdonald | 0 | Not applicable | 3.1 | Reardon, 201037 |
| Fenretinib | 23 | Not stated | 0 | Not applicable | 0 | Pudavalli, 200438 |
| Gefitinib | 57 | Macdonald | 0 | Not applicable | 13 | Rich, 200439 |
| Imatinib | 34 | Macdonald | 5.9 | Not stated | 3 | Wen, 200640 |
| Imatinib | 51 | Macdonald | 5.9 | > 6 months | 16 | Raymond, 200841 |
| Imatinib + hydroxyurea | 33 | Macdonald | 9 | Not stated | 27 | Reardon, 200542 |
| Imatinib + hydroxyurea | 231 | Macdonald | 3.4 | Not stated | 10.6 | Reardon, 200943 |
| Imatinib + hydroxyurea | 120 | Macdonald | 1.7 | Not stated | 7 | Dresemann, 201044 |
| Lapatinib | 17 | Levin | 0 | Not applicable | Not stated | Thiessen, 201045 |
| Temsirolimus | 65 | Macdonald | 0 | Not applicable | 7.8 | Galanis, 200546 |
| Tipifarnib | 676 | Macdonald | 7.5 | Not stated | 16.7 | Cloughesy, 200647 |
| Vorinostat | 66 | Macdonald | 3.0 | Not stated | 15.2 | Galanis, 200948 |
Abbreviations: ORR, objective response rate; PFS-6, objective response rate